company background image
300181 logo

Zhejiang Jolly PharmaceuticalLTD SZSE:300181 Stock Report

Last Price

CN¥14.80

Market Cap

CN¥10.4b

7D

-0.7%

1Y

25.0%

Updated

15 Jul, 2024

Data

Company Financials +

Zhejiang Jolly Pharmaceutical Co.,LTD

SZSE:300181 Stock Report

Market Cap: CN¥10.4b

300181 Stock Overview

Engages in the research, production, and marketing of Chinese medicinal products in the People’s Republic of China and internationally.

300181 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth6/6
Past Performance4/6
Financial Health6/6
Dividends4/6

Zhejiang Jolly Pharmaceutical Co.,LTD Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Zhejiang Jolly PharmaceuticalLTD
Historical stock prices
Current Share PriceCN¥14.80
52 Week HighCN¥17.28
52 Week LowCN¥8.36
Beta0.10
11 Month Change-4.02%
3 Month Change15.26%
1 Year Change25.00%
33 Year Change68.37%
5 Year Change175.61%
Change since IPO253.56%

Recent News & Updates

Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%

May 13
Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%

A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

May 08
A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

Recent updates

Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%

May 13
Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%

A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

May 08
A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

There's No Escaping Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Muted Earnings

Mar 01
There's No Escaping Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Muted Earnings

Shareholder Returns

300181CN PharmaceuticalsCN Market
7D-0.7%-0.6%1.2%
1Y25.0%-15.3%-18.5%

Return vs Industry: 300181 exceeded the CN Pharmaceuticals industry which returned -15.3% over the past year.

Return vs Market: 300181 exceeded the CN Market which returned -18.5% over the past year.

Price Volatility

Is 300181's price volatile compared to industry and market?
300181 volatility
300181 Average Weekly Movement7.4%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement6.7%
10% most volatile stocks in CN Market10.0%
10% least volatile stocks in CN Market4.3%

Stable Share Price: 300181 has not had significant price volatility in the past 3 months.

Volatility Over Time: 300181's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19952,687Tao Wangwww.zuoli.com

Zhejiang Jolly Pharmaceutical Co.,LTD engages in the research, production, and marketing of Chinese medicinal products in the People’s Republic of China and internationally. The company offers Wuling capsule that is used to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kidney, or neurasthenia. It also provides Lingze tablet, which is used to treat frequent urination, dysuria, weak steam of urine, endless urine, and soreness and weakness of waist and knees caused by benign prostatic hyperplasia, kidney deficiency, and blood stasis; and Bailing tablet that is used as the adjuvant therapy to treat cough, asthma, back pain, and chronic bronchitis, which are caused by the deficiency of lungs and kidney.

Zhejiang Jolly Pharmaceutical Co.,LTD Fundamentals Summary

How do Zhejiang Jolly PharmaceuticalLTD's earnings and revenue compare to its market cap?
300181 fundamental statistics
Market capCN¥10.38b
Earnings (TTM)CN¥427.90m
Revenue (TTM)CN¥2.12b

24.3x

P/E Ratio

4.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
300181 income statement (TTM)
RevenueCN¥2.12b
Cost of RevenueCN¥691.30m
Gross ProfitCN¥1.43b
Other ExpensesCN¥1.00b
EarningsCN¥427.90m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 30, 2024

Earnings per share (EPS)0.61
Gross Margin67.39%
Net Profit Margin20.19%
Debt/Equity Ratio6.4%

How did 300181 perform over the long term?

See historical performance and comparison

Dividends

3.0%

Current Dividend Yield

73%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.